Suven Pharmaceuticals (NSE:SUVENPHAR) ROCE % : 19.95% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Suven Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was 19.95%.

Suven Pharmaceuticals ROCE % Historical Data

The historical data trend for Suven Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals ROCE % Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

53.12

42.82

46.89

33.42

20.90

Suven Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															13.48	13.63	15.78	17.85	19.95

Suven Pharmaceuticals ROCE % Calculation

Suven Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	4131.226	/	( ( (19657.438 - 1587.659)	+	(22540.865 - 1068.957) )	/ 2 )
	=	4131.226	/	( (18069.779	+	21471.908)	/ 2 )
	=	4131.226	/	19770.8435
	=	20.90 %

Suven Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	4522.4	/	( ( (25055.6 - 2381.4)	+	(0 - 0) )	/ 1 )
	=	4522.4	/	( ( 22674.2	+	0 )	/ 1 )
	=	4522.4	/	22674.2
	=	19.95 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Suven Pharmaceuticals (NSE:SUVENPHAR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Suven Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (NSE:SUVENPHAR) » Definitions » ROCE %

Traded in Other Exchanges

543064:India

Address

No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Suven Pharmaceuticals Headlines

No Headlines